Colorectal cancer incidence is increasing among young adults in certain high-income countries.
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
None of the 45 patients who had a negative postoperative ctDNA value experienced a relapse after a median follow-up of 49 months.
The addition of nab-paclitaxel to gemcitabine-cisplatin appeared to confer clinical benefit in patients with advanced biliary tract cancers.
Administration of a single dose of oral aspirin prior to fecal immunochemical testing does not increase test sensitivity for detecting advanced colorectal neoplasms.
Rectal cancer patients with good tumor prognosis according to magnetic resonance imaging criteria may not need preoperative chemoradiotherapy.
RAS tumor status was not predictive of benefit from the combination of atezolizumab and cobimetinib compared with regorafenib.
Higher cardiorespiratory fitness (CRF) is associated with a lower risk for incident lung and colorectal cancer and with a lower risk for all-cause mortality among those diagnosed with lung and colorectal cancer.
The AGA present an updated summary of best practice advice for surveillance of hepatocellular cancer and DAA therapy timing.
This first-in-human trial will enroll up to 24 patients.
Fewer chemotherapy cycles could decrease long-term morbidity for certain patients.
Based on an interim analysis showing efficacy for postoperative docetaxel plus S-1 compared with S-1 alone, this trial in stage III gastric cancer was closed early.
There were more than 30,000 deaths due to liver cancer in the US during 2018.
NCCN guidelines currently say that an elevated serum CEA level is not a high-risk factor that would preclude the use of adjuvant chemotherapy for early-stage colorectal cancer.
Very few patients with resectable, locally advanced colon cancer included in the NCI-SEER database received adjuvant radiation therapy.
Decisions regarding whether to biopsy a peritoneal lesion in gastrointestinal cancer are often based on the physical appearance of the lesion.
The median number of prior treatments for patients with relapsed colorectal cancer enrolled in this phase 2 study was 6.
In 78% of patients, circulating cell-free tumor DNA identified a possible mechanism of acquired resistance not identified by standard tumor DNA sequencing.
The companion study arms under the COLOMATE trial umbrella will include those that specifically enroll patients with HER2-amplified or EGFR-mutant disease.
Regions of tumor and normal tissue on FFPE tissue specimens obtained from the NCI SEER-linked Virtual Tissue Repository were annotated by a pathologist.